Nuvation Bio (NUVB) Competitors

$4.78 -0.06 (-1.14%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$4.81 +0.02 (+0.52%)

As of 06:10 AM Eastern

NUVB vs. BLTE, TERN, CNTA, MIRM, and CGON

Should you buy Nuvation Bio stock or one of its competitors? MarketBeat compares Nuvation Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvation Bio include Belite Bio (BLTE), Terns Pharmaceuticals (TERN), Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Nuvation Bio compare to Belite Bio?

Nuvation Bio (NYSE:NUVB) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Nuvation Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, indicating that its share price is 219% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Nuvation Bio. Belite Bio is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	26.49	-$204.63M	-$0.43	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Belite Bio's return on equity of -19.49% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Belite Bio	N/A	-19.49%	-19.05%

In the previous week, Nuvation Bio had 1 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Nuvation Bio and 10 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.71 beat Nuvation Bio's score of 0.17 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio currently has a consensus target price of $12.50, indicating a potential upside of 161.23%. Belite Bio has a consensus target price of $202.33, indicating a potential upside of 31.80%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Nuvation Bio beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Terns Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Nuvation Bio currently has a consensus target price of $12.50, indicating a potential upside of 161.23%. Terns Pharmaceuticals has a consensus target price of $55.14, indicating a potential upside of 4.13%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Nuvation Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Terns Pharmaceuticals has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market.

Terns Pharmaceuticals has lower revenue, but higher earnings than Nuvation Bio. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	26.49	-$204.63M	-$0.43	N/A
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A

Terns Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Terns Pharmaceuticals' return on equity of -20.02% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Terns Pharmaceuticals	N/A	-20.02%	-19.37%

In the previous week, Nuvation Bio had 7 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 11 mentions for Nuvation Bio and 4 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.77 beat Nuvation Bio's score of 0.17 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Nuvation Bio beats Terns Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Centessa Pharmaceuticals currently has a consensus target price of $40.70, indicating a potential upside of 2.83%. Nuvation Bio has a consensus target price of $12.50, indicating a potential upside of 161.23%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Centessa Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Nuvation Bio. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.77	-$197.53M	-$1.79	N/A
Nuvation Bio	$62.90M	26.49	-$204.63M	-$0.43	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Nuvation Bio	-102.06%	-44.10%	-23.80%

In the previous week, Nuvation Bio had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 11 mentions for Nuvation Bio and 5 mentions for Centessa Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.17 beat Centessa Pharmaceuticals' score of -0.14 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nuvation Bio beats Centessa Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Nuvation Bio has a net margin of -102.06% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals currently has a consensus target price of $136.42, indicating a potential upside of 24.97%. Nuvation Bio has a consensus target price of $12.50, indicating a potential upside of 161.23%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Mirum Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.77	-$23.36M	-$13.61	N/A
Nuvation Bio	$62.90M	26.49	-$204.63M	-$0.43	N/A

In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Nuvation Bio. MarketBeat recorded 25 mentions for Mirum Pharmaceuticals and 11 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.36 beat Nuvation Bio's score of 0.17 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

CG Oncology has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. CG Oncology's return on equity of -23.33% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Nuvation Bio	-102.06%	-44.10%	-23.80%

CG Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CG Oncology currently has a consensus target price of $81.27, indicating a potential upside of 9.83%. Nuvation Bio has a consensus target price of $12.50, indicating a potential upside of 161.23%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

CG Oncology has higher earnings, but lower revenue than Nuvation Bio. CG Oncology is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,615.54	-$160.99M	-$2.33	N/A
Nuvation Bio	$62.90M	26.49	-$204.63M	-$0.43	N/A

In the previous week, CG Oncology had 25 more articles in the media than Nuvation Bio. MarketBeat recorded 36 mentions for CG Oncology and 11 mentions for Nuvation Bio. CG Oncology's average media sentiment score of 0.47 beat Nuvation Bio's score of 0.17 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	8 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CG Oncology beats Nuvation Bio on 9 of the 16 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.69B	$3.42B	$6.30B	$22.96B
Dividend Yield	N/A	2.30%	2.79%	4.07%
P/E Ratio	-11.13	18.67	21.03	28.29
Price / Sales	26.49	301.13	552.98	24.48
Price / Cash	N/A	122.51	42.94	25.11
Price / Book	5.20	6.75	9.82	4.73
Net Income	-$204.63M	$24.11M	$3.55B	$1.07B
7 Day Performance	-0.62%	-0.53%	-0.53%	-1.11%
1 Month Performance	-1.34%	0.34%	1.20%	1.36%
1 Year Performance	123.60%	78.62%	41.23%	24.41%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.059 of 5 stars	$4.79 -1.1%	$12.50 +161.2%	+118.5%	$1.69B	$62.90M	N/A	60
BLTE Belite Bio	2.7406 of 5 stars	$154.51 -0.2%	$202.33 +31.0%	+152.1%	$6.19B	N/A	N/A	10
TERN Terns Pharmaceuticals	2.22 of 5 stars	$52.97 +0.1%	$55.14 +4.1%	+1,725.9%	$6.11B	N/A	N/A	40
CNTA Centessa Pharmaceuticals	1.8801 of 5 stars	$39.70 +0.3%	$40.70 +2.5%	+217.7%	$5.90B	$15M	N/A	200
MIRM Mirum Pharmaceuticals	2.5226 of 5 stars	$105.79 +9.6%	$123.83 +17.1%	+141.1%	$5.89B	$521.31M	N/A	140	Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. BLTE, TERN, CNTA, MIRM, and CGON

How does Nuvation Bio compare to Belite Bio?

Summary

How does Nuvation Bio compare to Terns Pharmaceuticals?

Summary

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Summary

How does Nuvation Bio compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. BLTE, TERN, CNTA, MIRM, and CGON

How does Nuvation Bio compare to Belite Bio?

Which has more risk & volatility, NUVB or BLTE?

Which has better valuation & earnings, NUVB or BLTE?

Do insiders and institutionals have more ownership in NUVB or BLTE?

Is NUVB or BLTE more profitable?

Does the media prefer NUVB or BLTE?

Do analysts recommend NUVB or BLTE?

Summary

How does Nuvation Bio compare to Terns Pharmaceuticals?

Do analysts recommend NUVB or TERN?

Which has more risk & volatility, NUVB or TERN?

Which has better valuation & earnings, NUVB or TERN?

Is NUVB or TERN more profitable?

Does the media prefer NUVB or TERN?

Do insiders and institutionals have more ownership in NUVB or TERN?

Summary

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Do analysts recommend CNTA or NUVB?

Which has more volatility and risk, CNTA or NUVB?

Which has preferable valuation and earnings, CNTA or NUVB?

Is CNTA or NUVB more profitable?

Does the media prefer CNTA or NUVB?

Do institutionals and insiders have more ownership in CNTA or NUVB?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Is MIRM or NUVB more profitable?

Which has more volatility and risk, MIRM or NUVB?

Do institutionals and insiders have more ownership in MIRM or NUVB?

Do analysts recommend MIRM or NUVB?

Which has preferable valuation and earnings, MIRM or NUVB?

Does the media prefer MIRM or NUVB?

Summary

How does Nuvation Bio compare to CG Oncology?

Is CGON or NUVB more profitable?

Which has more risk and volatility, CGON or NUVB?

Do insiders & institutionals have more ownership in CGON or NUVB?

Do analysts recommend CGON or NUVB?

Which has better valuation & earnings, CGON or NUVB?

Does the media favor CGON or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools